Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
The pending Altria-Juul deal could lead to increased e-cigarette use or less cigarette use, depending on regulations and policies. Georgetown University professor David Levy explores the motivations behind the $12.8 billion purchase and its potential impact on public health.
Scientists have identified a cellular pathway that allows acute myeloid leukemia cells to evade the effects of drugs. They then engineered a compound that targets this pathway, blocking a mutant protein and halting the cancer cells' ability to sidestep the compound's effects.
The USPSTF recommends medications like tamoxifen, raloxifene, or aromatase inhibitors to reduce breast cancer risk in asymptomatic women over 35 with increased risk but low adverse effects risk. The Task Force advises against routine use for women not at high breast cancer risk.
A new study reveals a shift in obesity-associated cancers towards younger individuals, with significant increases in certain types of cancers among non-Hispanic Black and Hispanic women and men. The study found that the number of cases of these cancers increased by 25% to 400% in specific populations between 2000 and 2016.
A large international study found that cardiovascular disease (CVD) remains the leading cause of death worldwide, but its share has declined in high-income countries where cancer deaths have become more frequent. CVD risk factors are highest in rich countries, yet mortality rates are lower, suggesting other factors may be at play.
Researchers at Imperial College London found that hormone treatments can induce a dormant state in breast cancer cells, known as 'sleeper cells'. This could provide clues to why some cancers become resistant to treatment and may lead to new ways of preventing recurrence. Further research is needed to unlock the secrets of these cells.
Researchers identify CDK7 as a key player in prostate cancer growth and development, offering new treatment hope for metastatic castration-resistant prostate cancer (CRPC). Turning off CDK7 leads to the death of cancer cells, with limited off-target effects on healthy cells.
Researchers identified a drug combination that significantly extends patient survival in lung transplant recipients, offering a potential solution to the median survival rate of less than six years after transplantation. Sirolimus plus tacrolimus was associated with a better median survival than MMF plus tacrolimus.
Researchers have developed a hydrogel-based carrier that can deliver siRNAs directly to tumors, overcoming the challenge of rapid degradation and limited cellular entry. This innovative technology has the potential to improve the effectiveness of siRNA-based cancer treatments and enable more efficient delivery of biologics.
Researchers identified a molecule called DCAF15 that makes cancer cells more susceptible to natural killer cells. Blocking this molecule could lead to better survival rates for patients with acute myeloid leukemia.
A new drug, TAK-228, has demonstrated effectiveness in treating metastatic bladder cancer, slowing tumor growth and progression. The study found that four of seven patients showed a positive response to the treatment.
Oncologists suggest using nab-paclitaxel instead of paclitaxel prior to surgery for high-risk breast cancer patients, potentially improving long-term outcomes and reducing disease recurrence. This approach may be particularly beneficial for women with hormone receptor positive, HER-2 negative breast cancer.
Researchers at Flinders University have isolated a compound from the Australian white rock sea snail with antibacterial and anti-inflammatory properties, as well as important anti-cancer effects. The compound, part of the indole class, shows promise for preventing colon cancer tumor formation.
A recent study found that primary care physicians recommend health promotion to at least some cancer survivors, but oncologists and specialists rarely do. Cancer survivors face increased risks of cardiovascular disease if they don't adopt healthy lifestyles.
Researchers discovered an antibody drug that can destroy immune cells surrounding solid tumours, allowing T-cells to attack and kill cancer cells more effectively. The approach could improve treatments for various types of cancer, including CAR-T therapy.
The National Institute on Minority Health and Health Disparities has funded 11 research centers in minority institutions to foster the next generation of researchers and address health disparities. The centers will focus on diseases disproportionately affecting minority populations, including cancer, cardiometabolic diseases, and HIV/A...
Researchers identified a unique way to disrupt cellular process contributing to Diffuse Intrinsic Pontine Gliomas (DIPG). A vulnerability in the metabolic process for creating NAD was found, allowing for potential targeting of cancer cells with PPM1D mutation.
Researchers compared three frontline breast cancer drugs and found significant differences in their biological activity. Abemaciclib was shown to be more effective than other drugs at high doses, affecting proteins beyond CDK4/6, suggesting it may work differently for patients who don't respond to other treatments.
A clinical trial discovered that selinexor, a novel therapy, effectively knocked down bone marrow cancer in over a quarter of patients, including two who achieved complete remission. The treatment showed promise for patients resistant to multiple therapies and offered new hope for those with limited treatment options.
Researchers at CeMM Research Center have identified new targets for treating BAF mutant cancers by analyzing the effects of single subunit loss on chromatin accessibility and transcription. The study reveals that aberrant functions of remaining complexes may confer cancer-promoting properties, making them potentially druggable.
Researchers discovered a three-drug combination that sensitizes cancer cells to treatment, overcoming cross-therapy resistance. The approach involves time-sensitive administration of glucose-6-phosphate dehydrogenase inhibitors alongside other drugs.
Research found raised risks of blood clots, cardiomyopathy, and heart failure among cancer survivors, particularly those treated with chemotherapy. Long-term cardiovascular risks were elevated for over five years after diagnosis.
Researchers found that abemaciclib, a chemotherapeutic agent effective in breast cancer, has synergy when combined with HuR and YAP1 inhibitors to inhibit cell growth. The study suggests new targets for improving the efficacy of this drug and overcoming drug resistance in pancreatic cancer.
Researchers found that tumor cells depleted of ARID1A become highly sensitive to PARP inhibitor drugs after radiation treatment. This discovery could advance efforts to treat cancers resistant to current standard treatments.
A phase I trial is evaluating the combination of fecal transplants and immunotherapy for melanoma, with preliminary research suggesting a potential link between the human microbiome and treatment outcomes. Researchers aim to improve responses in 40-50% of patients treated with immunotherapy.
A recent study found that fewer than eight per cent of cancer drug trials included participation from all four major races in the US between 2008 and 2018. Black and Hispanic patients were particularly underrepresented, with rates of 22 per cent and 44 per cent respectively.
The observational study found significant changes in age distribution between obesity-associated and nonobesity-associated cancer cases over the 16-year period. The analysis revealed notable sex and racial disparities, with certain populations experiencing a higher risk of developing obesity-associated cancers at younger ages.
Researchers have identified a combination of treatments that may be more powerful than current therapy alone for children with Ewing sarcoma. The new approach combines FAK inhibitors with aurora kinase B targets to kill cancer cells and inhibit tumor progression.
Researchers at UCLA have developed a nanoscale capsule that breaks through the blood-brain barrier, allowing it to reach and treat cancer that has spread to the central nervous system. In mouse studies, this capsule delivered cancer-fighting drugs effectively eliminating B-cell lymphoma tumors.
A phase 1 clinical trial found that combining AZD1775, a Wee1 inhibitor, with radiation and gemcitabine resulted in better-than-expected overall survival in patients with locally advanced pancreatic cancer. The median overall survival was 22 months, surpassing previous results for the same treatment combination.
A University of Minnesota study found that high-fat foods significantly increase cannabidiol (CBD) absorption into the body. CBD exposure is vastly increased when taken with high fatty foods, and concentrations in the blood can be four times higher than fasting levels.
The study found that ERK was easily switched on in ancient one-celled creatures but carefully restrained as animals evolved. Researchers identified two key changes that likely brought ERK under more control across evolution.
A ketogenic diet has been shown to inhibit the growth of squamous cell carcinoma tumors in mice with lung cancer. The study also found a correlation between high blood glucose levels and poor survival among patients with squamous cell carcinoma.
The study examined 3,368 medical aid in dying prescriptions from Oregon (1998-2017) and Washington (2009-2017), finding that most patients were insured, non-Hispanic white individuals with cancer. The primary reasons for pursuing medical aid in dying were loss of autonomy, impaired quality of life, and loss of dignity.
Researchers develop innovative technology to transform proteins and antibodies into stable drug transporters, reducing side effects and increasing effectiveness in targeted cancer treatment. The new method allows for lower doses and fewer severe side effects compared to existing antibody-drug conjugates.
Researchers found that adding MS drug teriflunomide to targeted cancer therapy significantly shrinks glioblastoma tumors and improves mouse survival. The treatment targets cancer stem cells, which are responsible for tumor recurrence.
Researchers at Columbia University Irving Medical Center have identified a potential new therapy for pancreatic cancer. Their experimental compound, PTC596, has shown to be effective in combination with standard treatment, extending survival by three times in genetically engineered mice.
Researchers have identified a combination of gene mutations that are frequently found together in endometrial cancer and endometriosis-associated ovarian cancer. The ARID1A and PIK3CA genes' mutations can lead to uncontrolled cell growth, increasing the risk of cancer.
Researchers have identified a potential combination targeted therapy for a deadly type of leukemia found in some infants, which was linked to high levels of the BCL6 protein and poor outcomes. The therapy involves 'turning off' the BCL6 protein using ABT-199, promising a lifesaving treatment option for babies and young children.
Independent charity prescription drug assistance programs in the US primarily cover insured patients, leaving out those without health insurance. These programs tend to favor higher-priced brand-name drugs over generics.
Researchers used artificial intelligence to identify five new types of breast cancer with distinct patterns of response to treatment, including two that are more likely to benefit from immunotherapy. The study aims to personalize treatment for women with breast cancer by selecting patients for different drugs in clinical trials.
Biomedical researchers have created three-dimensional cell structures from diseased tissue of patients to study endometrial diseases like endometriosis and cancer. This new biobank can help unravel disorders and test drugs for effective treatments.
Researchers at Stanford University School of Medicine have discovered a new 'don't eat me' signal used by cancer cells to evade immune detection. Blocking this signal allows immune cells to attack and destroy cancer cells in mice implanted with human cancers, providing a potential basis for new anti-cancer therapies.
A phase-3 trial shows that combining rituximab with ibrutinib keeps patients disease-free for nearly three years and improves overall survival rates. The new treatment is more effective and better tolerated than traditional chemotherapy, revolutionizing the standard of care for chronic lymphocytic leukemia.
Researchers at the University of Birmingham have successfully extracted and modified a compound from feverfew to kill chronic lymphocytic leukemia cells in laboratory experiments. The compound, parthenolide, works by increasing reactive oxygen species levels in cancer cells, causing them to die.
The National Cancer Institute has recognized Sylvester Comprehensive Cancer Center as a top-tier US cancer center due to its outstanding research and clinical care. The designation is a testament to the dedication of every member of the cancer center.
Researchers analyzed 10,225 patient samples from 32 different cancers to better understand TP53 mutations. They found that TP53 mutations were more frequent in patients with poorer survival rates but also identified a way to predict prognosis based on four upregulated genes.
Researchers at Tokyo University of Agriculture and Technology have developed a novel experimental model for dog bladder cancer using 3D organoid culture from urine samples. The model allows for quick determination of chemotherapy and identification of new biomarkers for both human and canine bladder cancer.
Researchers at UVA have identified Hullk, a non-coding RNA that regulates biological processes in cells. The discovery offers potential for targeting and stopping prostate cancer progression with fewer side effects.
A breakthrough new drug CBL0137 has proven effective in mice treated with chemotherapy and is being tested as a potential treatment for all types of cancer, including solid tumours. The drug works by reactivating the body's P53 pathway to kill off damaged cells.
Australian researchers have identified a gene called JMJD6 that plays a key role in the most aggressive form of neuroblastoma. The discovery opens up new possibilities for targeted drug therapy, with promising results shown in animal models.
The freely available data set includes unique comparisons of almost 1,000 cancer cell lines' responses to 453 licensed and experimental drugs. The dataset offers a rich resource for cancer scientists to discover more about how cancer cells work and generate new therapeutics and drug combinations.
A study published in JAMA Oncology reports higher than expected five-year survival rates for patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer treated with nivolumab. The treatment showed durable responses and improved outcomes for patients without cancer-related symptoms.
A new, non-invasive bladder cancer treatment method uses a 'liquid biopsy' from urine to identify molecular underpinnings of each patient's unique bladder cancer. The technique, called conditional reprogramming or CR, has shown promising results in detecting and treating the disease.
A combination of two FDA-approved drugs significantly extended the lives of mice injected with human ovarian cancer cells, altering the natural ratio of macrophages and improving survival. The treatment targets M1 macrophages, which can protect against tumor growth and progression.
A new study published in Science Advances reveals that a cellular switch called CREB plays a key role in directing tumor growth in non-small-cell lung cancer. Researchers found that blocking this switch could have therapeutic benefits for patients with this deadly type of cancer.
Researchers at UT Southwestern Medical Center discovered a new molecular mechanism that indicates PARP inhibitors could be effective in treating all cancers where the drugs are used, including ovarian and prostate cancers. A potential biomarker has been identified, which may indicate when patients can benefit from these drugs.
The FDA has approved erdafitinib as a targeted therapy for patients with advanced bladder cancer who have specific gene mutations in the FGFR3 gene. The drug achieved a 40% overall response rate and was well-tolerated, offering an alternative to existing treatments.
A study by University of Notre Dame researcher Siyuan Zhang and collaborators identified a gene that makes triple-negative breast cancer (TNBC) cells vulnerable to existing therapies. The discovery suggests that a targeted drug therapy may be effective for this aggressive type of breast cancer.
Researchers at Vanderbilt University Medical Center investigated a cancer patient's fatal encephalitis after immunotherapy treatment, revealing a rare viral infection trigger. The study found that a specific T cell population may play a major role in immune-related adverse events and anti-tumor responses.